What's happening
This bill requires prescription drug manufacturers to notify the state before raising wholesale drug prices by more than 10%.
Why it matters
Increases transparency around drug pricing by requiring manufacturers to publicly justify and disclose significant price hikes. including whether a change or improvement in the drug necessitates the increase—potentially deterring unjustified price spikes.
Empowers the state to hold manufacturers accountable. by imposing fines of up to $5,000 per day for failure to report required information, creating a financial incentive for compliance.
Provides consumers, insurers, and policymakers with advance notice (at least 60 days) of major price increases. , allowing for more informed decision-making, possible budget adjustments, and time to explore alternatives.
Limits public disclosure of confidential business information by protecting trade secrets. , but still ensures aggregate pricing data can be published to inform the public and support policy analysis.
Albany, before your first meeting.
Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.
Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.
Who cares
Prescription drug manufacturers
Covered manufacturers would have to give 60 days’ notice of wholesale acquisition cost increases exceeding 10 percent, counting increases over the previous 24 months, for drugs costing more than $40 per course of therapy, or face penalties of up to $5,000 per day for failing to report.
Department of Financial Services
The superintendent would receive price-increase notices, publish them on the department’s website within five days, protect manufacturer-designated trade secrets and enforce reporting requirements.
Health insurers and pharmacy benefit managers
Notices would provide advance information about qualifying price increases for drugs they purchase or reimburse in New York.
Patients taking prescription drugs
Published notices would offer advance information about qualifying wholesale price increases and whether manufacturers attribute them to a change or improvement in the drug.
Headline styles
Notify State of Drug Price Hikes
Plain English, a few words. Used as the page title.
Sponsors
1 Co-sponsor
History
- Referred to health
- Delivered to assembly
- Passed senateVote 48–13
- Advanced to third reading
- Amended 7499b
- 2nd report cal.
- 1st report cal.1338
- Print number 7499a
- Amend (t) and recommit to health
- Referred to health
- Referred to rules
Companion bill
The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.
Notify State Before Drug Price Hikes
In Assembly Committee · Health · Sponsor Daniel Rosenthal
Full text
2 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗
STATE OF NEW YORK
7499--B Cal. No. 1338
2021-2022 Regular Sessions
IN SENATE
November 3, 2021
Introduced by Sens. SALAZAR, MAY -- read twice and ordered printed, and when printed to be committed to the Committee on Rules -- recommitted to the Committee on Health in accordance with Senate Rule 6, sec. 8 -committee discharged, bill amended, ordered reprinted as amended and recommitted to said committee -- reported favorably from said committee, ordered to first and second report, amended on second report, ordered to a third reading, and to be reprinted as amended, retaining its place in the order of third reading
AN ACT to amend the insurance law, in relation to requiring certain manufacturers of prescription drugs to notify the superintendant of any proposed increase of the wholesale acquisition cost of such prescription drugs
The People of the State of New York, represented in Senate and Assembly, do enact as follows:
Section 1. The insurance law is amended by adding a new section 111-a to read as follows:
§ 111-a. Notification of prescription drug price increases by manufacturers. (a) This section shall apply to a manufacturer of a prescription drug that is purchased or reimbursed in this state by any of the following:
(1) An insurance company authorized in this state to write accident and health insurance, a company organized pursuant to article fortythree of this chapter, a municipal cooperative health benefit plan established pursuant to article forty-seven of this chapter, an organization certified pursuant to article forty-four of the public health law, an institution of higher education certified pursuant to section one thousand one hundred twenty-four of this chapter, or the New York state health insurance plan established pursuant to article eleven of the civil service law; or
(2) A pharmacy benefit manager, including an entity that directly or through an intermediary, manages the prescription drug coverage provided by a health insurer under a contract or policy delivered or issued for delivery in this state or a health plan subject to section three hundred sixty-four-j of the social services law, including the processing and
EXPLANATION--Matter in italics (underscored) is new; matter in brackets
[ ] is old law to be omitted.
LBD05130-04-2
payment of claims for prescription drugs, the performance of drug utilization review, the processing of drug prior authorization requests, the adjudication of appeals or grievances related to prescription drug coverage, contracting with network pharmacies, and controlling the cost of covered prescription drugs.
(b) (1) A manufacturer of a prescription drug with a wholesale acquisition cost of more than forty dollars for a course of therapy shall notify the superintendent, his or her deputy or other officer designated by the superintendent, if the increase in the wholesale acquisition cost of such prescription drug is more than ten percent, including the proposed increase and the cumulative increases that occurred within the previous twenty-four months. For purposes of this section, a "course of therapy" is defined as either of the following:
(i) the recommended daily dosage units of a prescription drug pursuant to its prescribing label as approved by the federal Food and Drug Administration for thirty days; or
(ii) the recommended daily dosage units of a prescription drug pursuant to its prescribing label as approved by the federal Food and Drug Administration for a normal course of treatment that is less than thirty days.
(2) (i) The notice required by paragraph (1) of this subsection shall be provided in writing to the superintendent at least sixty days prior to the planned effective date of the increase and shall include the proposed increase and the cumulative increases that occurred within the previous twenty-four months.
(ii) The superintendent shall forthwith publish the notice required by paragraph (a) of this subdivision on the department of financial services website within five days of its receipt.
(3) (i) The notice required by paragraph (1) of this subsection shall include the date of the increase, the current wholesale acquisition cost of the prescription drug, and the dollar amount of the future increase in the wholesale acquisition cost of the prescription drug.
(ii) The notice required by paragraph (1) of this subsection shall include a statement regarding whether a change or improvement in the drug necessitates the price increase. If so, the manufacturer shall describe the change or improvement.
(4) Information supplied by a manufacturer pursuant to this section that the manufacturer has designated as a trade secret shall be considered confidential and a trade secret and shall not be disclosed directly or indirectly by the superintendent. Notwithstanding the foregoing sentence, the superintendent shall be permitted to disclose information in an aggregated format if such aggregate information cannot directly or indirectly be used to identify trade secret information related to a specific manufacturer or the manufacturer's prescription drug, including but not limited to any information related to pricing for the manufacturer's prescription drug that has been designated as a trade secret.
(5) In the event that a manufacturer of a prescription drug subject to this section does not report the information required in paragraph (1) of this subsection, the superintendent is authorized to impose any penalty or remedy authorized by this chapter, after notice and a hearing, against such manufacturer of up to five thousand dollars per day for every day after the reporting period described in this section that the required information is not reported.
§ 2. This act shall take effect immediately.
Reflowed for reading: line numbers and page breaks removed. Cite the official text.
Sponsor's memo
Title of bill
An act to amend the insurance law, in relation to requiring certain manufacturers of prescription drugs to notify the superintendant of any proposed increase of the wholesale acquisition cost of such prescription drugs
Purpose
This bill would require manufacturers to provide at least 60 day notice Of their intent to raise wholesale prescription drug costs to the Department of Financial Services if the increase is 10% or more of the total cost of the drug.
Summary of provisions
Section 1 amends the insurance law to add new section 111-a relating to notification of prescription drug price increases by manufacturers.
Section 2 provides the effective date.
Justification
This legislation will provide early warning of increases in the price of prescription drugs. Breakthrough medications offer tremendous clinical benefits for patients, but they should not be a blank check. The prices charged for prescription drugs are a major threat to keeping health care affordable for New York employers and consumers. Exorbitant increases in prescription drug prices have been consistent across all segments of the pharmaceutical industry. For example, in 2016 Mylan increased the price for a package of two EpiPen Auto-Injectors from just over $100 to more than $600 without any warning or public justification. Since the start of 2019, more than two dozen drug makers have raised the prices on a wide array of drugs by double-digit percentages.
The bill will not prohibit manufacturers from increasing prices, but would require notice of price increases, enhancing transparency of prescription drug costs. Providing notice before a price increase of more than 10 percent takes effect is important so that consumers, employers, providers, health plans and the state are prepared and can take steps before. the increase is implemented. It would also be impor- tant for the policymakers to be provided with the rationale for the increase including whether the price increases will benefit the public to help fund research and development that improve patient care or will it merely result in increasing the cost of health care.
Amended bill
The B-print of the bill makes several minor clarifying changes and establishes a clear process by which alleged "trade secret" information must be disclosed to the Department but is only released publicly in aggregate form. The B-print also modifies the penalty that, can be imposed by DFS on drug manufacturing companies found to have failed to report the required information to the Department.
Legislative history
2019 & 2020 S5942 / A8253 - Referred to Health Committees in both hous- es.
Fiscal implications
None.
Effective date
This act shall take effect immediately.
Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.